[go: up one dir, main page]

MX2022007911A - Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7. - Google Patents

Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.

Info

Publication number
MX2022007911A
MX2022007911A MX2022007911A MX2022007911A MX2022007911A MX 2022007911 A MX2022007911 A MX 2022007911A MX 2022007911 A MX2022007911 A MX 2022007911A MX 2022007911 A MX2022007911 A MX 2022007911A MX 2022007911 A MX2022007911 A MX 2022007911A
Authority
MX
Mexico
Prior art keywords
tlr7 agonist
virus infection
treating virus
methods
treating
Prior art date
Application number
MX2022007911A
Other languages
English (en)
Inventor
Qingyan Bo
Yuyan Jin
Gaurav Tyagi
Yonghong Zhu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022007911A publication Critical patent/MX2022007911A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a procedimientos de tratamiento de la infección por HBV, COVID-19 o SARS-CoV-2 en un paciente humano, en los que los procedimientos comprenden la administración de una cantidad terapéuticamente eficaz de un agonista de TLR7, o una sal farmacéuticamente aceptable del mismo.
MX2022007911A 2019-12-24 2020-12-22 Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7. MX2022007911A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019127972 2019-12-24
CN2020112137 2020-08-28
PCT/EP2020/087561 WO2021130195A1 (en) 2019-12-24 2020-12-22 Method of treating virus infection using a tlr7 agonist

Publications (1)

Publication Number Publication Date
MX2022007911A true MX2022007911A (es) 2022-07-21

Family

ID=74175821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007911A MX2022007911A (es) 2019-12-24 2020-12-22 Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.

Country Status (11)

Country Link
US (1) US20230044958A1 (es)
EP (1) EP4081216A1 (es)
JP (1) JP2023509869A (es)
KR (1) KR20220119616A (es)
CN (1) CN115103674A (es)
AU (1) AU2020415307A1 (es)
CA (1) CA3162008A1 (es)
IL (1) IL294161A (es)
MX (1) MX2022007911A (es)
TW (1) TW202135820A (es)
WO (1) WO2021130195A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3108033B1 (fr) * 2020-03-10 2023-04-21 Univ Claude Bernard Lyon COMPOSES ANTIVIRAUX ET LEURS COMBINAISONS POUR TRAITER L’INFECTION VIRALE PAR LE SARS-CoV-2
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
CN113476600B (zh) * 2021-07-09 2023-05-30 海南大学 Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物
KR102654464B1 (ko) 2021-09-24 2024-04-09 바이로큐어 주식회사 레오바이러스 기반 신규한 백신플랫폼 및 이의 용도
KR20240143930A (ko) 2023-03-21 2024-10-02 바이로큐어 주식회사 종양항원 암백신 플랫폼 및 이의 용도
WO2025055944A1 (en) * 2023-09-11 2025-03-20 Zhang John Qi Treatment and prevention of hepatitis b using covid-19 vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
JP6306750B2 (ja) 2014-03-07 2018-04-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療および予防のための新規な６−縮合ヘテロアリールジヒドロピリミジン
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
SI3230298T1 (sl) 2014-12-08 2021-04-30 F. Hoffmann-La Roche Ag Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom
HRP20200943T1 (hr) * 2015-03-16 2020-09-18 F. Hoffmann - La Roche Ag Kombinirani tretman s agonistom tlr7 i inhibitorom hbv kapside

Also Published As

Publication number Publication date
WO2021130195A1 (en) 2021-07-01
CA3162008A1 (en) 2021-07-01
JP2023509869A (ja) 2023-03-10
AU2020415307A1 (en) 2022-06-09
US20230044958A1 (en) 2023-02-09
TW202135820A (zh) 2021-10-01
CN115103674A (zh) 2022-09-23
IL294161A (en) 2022-08-01
KR20220119616A (ko) 2022-08-30
EP4081216A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
MX2021002321A (es) Nuevos metodos.
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
MX2021002322A (es) Nuevos metodos.
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
PH12021553180A1 (en) Inhibitors of human immunodeficiency virus replication
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
PH12021552191A1 (en) Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
PH12021550632A1 (en) Monomer and multimeric anti-hbv agents
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
EA201991618A1 (ru) Кристаллические формы тебипенема пивоксила, композиции, содержащие их, способы изготовления и способы применения
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
MX2018000240A (es) Metodos para tratar el vhc.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2020011453A (es) Combinaciones para tratar el cancer.
WO2020243273A3 (en) Methods of treating cholangiocarcinoma